- Home
- NODK vs STRO Comparison
NODK vs STRO Comparison
Compare NODK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- STRO
- Stock Information
- Founded
- NODK 1946
- STRO 2003
- Country
- NODK United States
- STRO United States
- Employees
- NODK N/A
- STRO N/A
- Industry
- NODK Property-Casualty Insurers
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- STRO Health Care
- Exchange
- NODK Nasdaq
- STRO Nasdaq
- Market Cap
- NODK 322.1M
- STRO 292.6M
- IPO Year
- NODK 2017
- STRO 2018
- Fundamental
- Price
- NODK $15.27
- STRO $4.25
- Analyst Decision
- NODK
- STRO Strong Buy
- Analyst Count
- NODK 0
- STRO 8
- Target Price
- NODK N/A
- STRO $12.13
- AVG Volume (30 Days)
- NODK 31.2K
- STRO 496.5K
- Earning Date
- NODK 11-15-2024
- STRO 11-19-2024
- Dividend Yield
- NODK N/A
- STRO N/A
- EPS Growth
- NODK N/A
- STRO N/A
- EPS
- NODK N/A
- STRO N/A
- Revenue
- NODK $380,700,000.00
- STRO $169,359,000.00
- Revenue This Year
- NODK N/A
- STRO N/A
- Revenue Next Year
- NODK N/A
- STRO N/A
- P/E Ratio
- NODK N/A
- STRO N/A
- Revenue Growth
- NODK 15.43
- STRO 197.83
- 52 Week Low
- NODK $12.02
- STRO $2.01
- 52 Week High
- NODK $16.55
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- NODK 56.81
- STRO 64.22
- Support Level
- NODK $15.37
- STRO $3.22
- Resistance Level
- NODK $16.09
- STRO $3.74
- Average True Range (ATR)
- NODK 0.22
- STRO 0.24
- MACD
- NODK 0.01
- STRO 0.08
- Stochastic Oscillator
- NODK 70.93
- STRO 78.99
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.